Cogent Biosciences, Inc. (COGT)

NMS – Real vaqt narxi. Valyuta: USD

37.87

-0.83 (-2.14%)

Bozor ochiq: Aug 12, 2026, 11:23 AM EDT

39.45

+0.75 (1.94%)

Oldingi bozordan keyin: Aug 11, 2026, 7:45 PM EDT

10.08.2026

Cogent Biosciences Reports Recent Business Highlights and Second Quarter 2026 Financial Results

On track for potential approval of bezuclastinib for GIST patients (PDUFA November 30) and NonAdvSM patients (PDUFA December 30) later this year; AdvSM New Drug Application submitted to FDA on June 30 Completed onboarding of expert cross-functional Cogent customer-facing team, including all field-based commercial and medical team members Strong pro forma cash balance of $865.9 million, sufficient to fund operations into late 2028 WALTHAM, Mass. and BOULDER, Colo.

Videolar

No Data

There is no data to display

Press-relizlar

10.08.2026

Cogent Biosciences, Inc. (COGT)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Cogent Biosciences, Inc. (COGT)

Cogent Biosciences Reports Recent Business Highlights and Second Quarter 2026 Financial Results

Videolar

No Data

Press-relizlar

Cogent Biosciences Reports Recent Business Highlights and Second Quarter 2026 Financial Results

Cogent Biosciences Reports Recent Business Highlights and Second Quarter 2026 Financial Results

Videolar

No Data

Press-relizlar

Cogent Biosciences Reports Recent Business Highlights and Second Quarter 2026 Financial Results

Search stocks

Cogent Biosciences, Inc. (COGT)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Cogent Biosciences, Inc. (COGT)

Cogent Biosciences Reports Recent Business Highlights and Second Quarter 2026 Financial Results

Videolar

No Data

Press-relizlar

Cogent Biosciences Reports Recent Business Highlights and Second Quarter 2026 Financial Results

Cogent Biosciences Reports Recent Business Highlights and Second Quarter 2026 Financial Results

Videolar

No Data

Press-relizlar

Cogent Biosciences Reports Recent Business Highlights and Second Quarter 2026 Financial Results